Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 8;9(8):981–993. doi: 10.1158/2326-6066.CIR-20-0814

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.

PMC Copyright notice

Figure 3. — Viral peptides homologous to tumor antigens can reduce tumor growth in already established tumors. A, C57BL/6J mice were subcutaneously injected with B16-OVA or B16-F10 cells at day 0. As soon the tumors were visible, the mice were treated with either PBS (mock; n = 8), Ad5-Δ24-CpG alone (uncoated virus; n = 8), Ad5-Δ24-CpG coated with viral-derived peptides similar to TRP2_180–188 (Viral-PeptiCRAd; n = 8), or Ad5-Δ24-CpG coated with TRP2_180–188 peptide (TRP2-PeptiCRAd; n = 8). Normalized B16-OVA (B) and B16-F10 (C) tumor volume is shown as mean ± SEM (statistical analysis by two-way ANOVA with multiple comparison). Normalized B16-OVA (D) and B16-F10 (E) tumor volume curves of individual mice per each group. The dotted line identifies the therapeutic success threshold and represents the median of the normalized volumes measured at the endpoint. P value is represented as follows: >0.05 (ns), ≤0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).